readthroughSign in
Nov 9, 2026People

Myriad Genetics grants retention stock options to top executives

The board's compensation committee approved one-time option awards for named executive officers on November 6, 2026, vesting after three years of continued service.

Myriad Genetics disclosed in an 8-K filing that on November 6, 2026, the Compensation and Human Capital Committee of its board of directors approved one-time equity awards in the form of stock options for certain executive officers of the company, including its named executive officers, in order to promote the retention and continuity of the company's leadership as the company executes on initiatives designed to improve operational efficiencies and financial performance.1

The awards were issued under the company's 2026 Employee, Director and Consultant Equity Incentive Plan. Benjamin R. Wheeler, Chief Financial Officer, received options covering 121,379 shares; Mark S. Verratti, Chief Operating Officer, received 146,933 shares; and Dale Muzzey, Chief Scientific Officer, received 92,632 shares. Each award carries an exercise price equal to the closing stock price on the grant date.1

The options have specific vesting and expiration terms. They vest and become exercisable on the third anniversary of the grant date, subject to the recipient's continued service through that date and the plan's terms.1 Each award has a ten-year term, subject to earlier termination under the plan and agreement.1

Termination provisions were also outlined. If a recipient's service ends for reasons other than death, disability, or cause, any vested portion generally remains exercisable for three months after termination; a termination for cause ends the option immediately, whether vested or not.1 Any termination of employment will also be subject to the recipient's existing Severance and Change in Control Agreement with the company.1

The filing noted that the description of the awards is qualified by the form of stock option agreement, filed as Exhibit 10.1 to the report.1 The 8-K was signed by Benjamin R. Wheeler, Chief Financial Officer, on November 9, 2026.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.